These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18558435)

  • 21. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts.
    Sugiyama A
    Br J Pharmacol; 2008 Aug; 154(7):1528-37. PubMed ID: 18552873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM
    J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs for men and women - how important is gender as a risk factor for TdP?
    Coker SJ
    Pharmacol Ther; 2008 Aug; 119(2):186-94. PubMed ID: 18472167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced QT dispersion: does it predict the risk of torsade de pointes?
    Shah RR
    J Electrocardiol; 2005 Jan; 38(1):10-8. PubMed ID: 15660342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Importance of extracardiac alpha1-adrenoceptor stimulation in assisting dofetilide to induce torsade de pointes in rabbit hearts.
    Farkas AS; Acsai K; Tóth A; Dézsi L; Orosz S; Forster T; Csanády M; Papp JG; Varró A; Farkas A
    Eur J Pharmacol; 2006 May; 537(1-3):118-25. PubMed ID: 16618484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
    Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A search to predict potential for drug-induced cardiovascular toxicity.
    Hamlin RL
    Toxicol Pathol; 2006; 34(1):75-80. PubMed ID: 16507547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-induced torsades de pointes in patients aged 80 years or more.
    Paran Y; Mashav N; Henis O; Swartzon M; Arbel Y; Justo D
    Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proarrhythmic potential of antimicrobial agents.
    Simkó J; Csilek A; Karászi J; Lorincz I
    Infection; 2008 Jun; 36(3):194-206. PubMed ID: 18454341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moxifloxacin-induced torsades de pointes.
    Sherazi S; DiSalle M; Daubert JP; Shah AH
    Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experimental models of torsades de pointes].
    Davy JM; Weissenburger J; Chezalviel F; Ertzbischoff O
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():15-21. PubMed ID: 1307190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Male/female differences in pharmacology: safety issues with QT-prolonging drugs.
    Anthony M
    J Womens Health (Larchmt); 2005; 14(1):47-52. PubMed ID: 15692277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the pro-arrhythmic potential of anti-arrhythmic drugs: an experimental approach.
    Verduyn SC; van Opstal JM; Leunissen JD; Vos MA
    J Cardiovasc Pharmacol Ther; 2001 Jan; 6(1):89-97. PubMed ID: 11452340
    [No Abstract]   [Full Text] [Related]  

  • 35. Increasing gap junction coupling reduces transmural dispersion of repolarization and prevents torsade de pointes in rabbit LQT3 model.
    Quan XQ; Bai R; Liu N; Chen BD; Zhang CT
    J Cardiovasc Electrophysiol; 2007 Nov; 18(11):1184-9. PubMed ID: 17711442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes.
    Detre E; Thomsen MB; Beekman JD; Petersen KU; Vos MA
    Br J Pharmacol; 2005 Jun; 145(3):397-404. PubMed ID: 15778734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.
    Aubert M; Osterwalder R; Wagner B; Parrilla I; Cavero I; Doessegger L; Ertel EA
    Drug Saf; 2006; 29(3):237-54. PubMed ID: 16524323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
    Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
    J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II.
    Testai L; Breschi MC; Martinotti E; Calderone V
    J Appl Toxicol; 2007; 27(3):270-5. PubMed ID: 17265420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia.
    Akita M; Shibazaki Y; Izumi M; Hiratsuka K; Sakai T; Kurosawa T; Shindo Y
    J Toxicol Sci; 2004 Feb; 29(1):63-71. PubMed ID: 15018156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.